Literature DB >> 17054712

Investigation of the effects of sulfonylurea exposure on pancreatic beta cell metabolism.

Lorraine Brennan1, Chandralal Hewage, J P G Malthouse, Neville H McClenaghan, Peter R Flatt, Philip Newsholme.   

Abstract

Prolonged exposure of pancreatic beta cells to the sulfonylureas glibencamide and tolbutamide induces subsequent desensitization to the actions of these drugs. The precise mechanisms underlying this desensitization remain unknown, prompting the present study, which investigated the impact of prolonged sulfonylurea exposure on glucose and energy metabolism using clonal pancreatic BRIN-BD11 beta cells. Following prolonged exposure to tolbutamide, BRIN-BD11 beta cells were incubated in the presence of [U-(13)C]glucose, and isotopomer analysis revealed that there was a change in the ratio of flux through pyruvate carboxylase (EC 6.4.1.1) and pyruvate dehydrogenase (EC 1.2.4.1, EC 2.3.1.12, EC 1.8.1.4). Energy status in intact BRIN-BD11 cells was determined using (31)P-NMR spectroscopy. Exposure to tolbutamide did not alter the nucleotide triphosphate levels. Collectively, data from the present study demonstrate that prolonged exposure of beta cells to tolbutamide results in changes in flux through key enzymes involved in glucose metabolism that, in turn, may impact on glucose-induced insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17054712     DOI: 10.1111/j.1742-4658.2006.05513.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  2 in total

Review 1.  The pyruvate carboxylase-pyruvate dehydrogenase axis in islet pyruvate metabolism: Going round in circles?

Authors:  Mary C Sugden; Mark J Holness
Journal:  Islets       Date:  2011-11-01       Impact factor: 2.694

2.  Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea.

Authors:  Tada Kunavisarut; Sutin Sriussadaporn; Raweewan Lertwattanarak
Journal:  Diabetes Metab Syndr Obes       Date:  2019-05-21       Impact factor: 3.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.